Last reviewed · How we verify
NCT05378854: LC_SSP
Training Data Collection & AI Development
NA trial testing LifeChamps Platform in Breast Cancer in 27 participants. Completed in 10 April 2023.
10 April 2023
Quick facts
| Lead sponsor | Aristotle University Of Thessaloniki |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 27 |
| Start date | 31 July 2022 |
| Primary completion | 10 April 2023 |
| Estimated completion | 10 April 2023 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- LifeChamps Platform
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Aristotle University Of Thessaloniki
Who can join
65 and older, any sex, with Breast Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to facilitate collection of real-world data to test and train the analytics engine for each prototype algorithm. Preliminary datasets will be generated to enable a dry run of the prototype algorithms to check their predictive functionality as part of simulated 'experimental' scenarios at each LifeChamps partner site. This preparatory work will be critical to the development of the LifeChamps platform, prior to progressing to a larger scale feasibility trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05378854
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LifeChamps Platform
Trials testing the same drug.
- NCT05797727 — Real-Life Pilot Feasibility Study (LC_RLP) · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Aristotle University Of Thessaloniki trials
Trials by the same sponsor.
- NCT07382479 — NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery · NA · not yet recruiting
- NCT07379905 — MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) · NA · not yet recruiting
- NCT07335016 — The Role of Follicular Flushing at Oocyte Retrieval · NA · not yet recruiting
- NCT07297121 — Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece. · not yet recruiting
- NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05378854 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aristotle University Of Thessaloniki
- Last refreshed: 18 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05378854.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing